R. McCrimmon

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
R.j Mccrimmon, R. J. Mccrimmon, R J Mccrimmon, Rory Mccrimmon, Rory John Mccrimmon, R. Mccrimmon, Rory J. Mccrimmon, Rory J Mccrimmon
Publication record
314 papers · 14,397 citations · H-index 54

PAPERS

'There is more to life than HbA1c': A comprehensive qualitative framework from the Hypo-RESOLVE project evidencing the impacts of hypoglycaemia on the quality of life of adults living with type 1 or type 2 diabetes.
20260 citationsauthor #10
Assessing thoughts, feelings and behaviours related to hypoglycaemia: Psychometric evaluation of the Hypoglycaemia Cues Questionnaire (HypoC-Q).
20260 citationsauthor #6
Correction: Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy
20260 citationsauthor #18
Real-world initiation of continuous glucose monitoring (CGM) in adults with type 1 diabetes leads to increased body mass index - A brief report from IMI-SOPHIA study.
20250 citationsauthor #2
Activation of the Nrf2 Pathway by Sulforaphane Improves Hypoglycaemia-Induced Cognitive Impairment in a Rodent Model of Type 1 Diabetes
20254 citationsauthor #6
One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
20251 citationsauthor #3
The Ancient Drug Salicylate Indirectly Targets Fructose‐1,6‐Bisphosphatase to Suppress Liver Glucose Production in Diet‐Induced Obese Mice
20250 citationsauthor #6
Recurrent hypoglycaemia promotes cardiomyopathy and cardiac vulnerability in a rodent model of type 1 diabetes
20250 citationsauthor #11
Exploring the potential role of C‐peptide in type 2 diabetes management
20257 citationsauthor #2
Deep-learning prediction of cardiovascular outcomes from routine retinal images in individuals with type 2 diabetes
202520 citationsauthor #5
Causes and clinical consequences of low concordance between sensor-detected and person-reported hypoglycaemia
20250 citationsauthor #3
SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
20250 citationsauthor #2
Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort
20250 citationsauthor #6
Body Mass Index's influence on arterial hypertension in Type 1 diabetes - A brief report from IMI-SOPHIA study.
20243 citationsauthor #3
A Comparison of the Rates of Clock-Based Nocturnal Hypoglycemia and Hypoglycemia While Asleep Among People Living with Diabetes: Findings from the Hypo-METRICS Study
20246 citationsauthor #15
Real‐life hypoglycaemia partially blunts the inflammatory response to experimental hypoglycaemia in people with type 1 diabetes
20240 citationsauthor #6
Associations Between Hypoglycemia Awareness Status and Symptoms of Hypoglycemia Among Adults with Type 1 or Insulin-Treated Type 2 Diabetes Using the Hypo-METRICS Smartphone Application
20242 citationsauthor #15
Correction to: Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia
20240 citationsauthor #7
Incremental Prognostic Value of a Coronary Heart Disease Polygenic Risk Score in Type 2 Diabetes.
20242 citationsauthor #4
Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials
20245 citationsauthor #13
HIT4HYPOS Continuous Glucose Monitoring Data Analysis: The Effects of High-Intensity Interval Training on Hypoglycemia in People With Type 1 Diabetes and Impaired Awareness of Hypoglycemia
20242 citationsauthor #5
Correction: Chronic hyperglycaemia increases the vulnerability of the hippocampus to oxidative damage induced during post-hypoglycaemic hyperglycaemia in a mouse model of chemically induced type 1 diabetes
20240 citationsauthor #10
Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes: the Hypo-RESOLVE hypoglycaemic clamp study
20244 citationsauthor #6
Associations of clinical, psychological, and sociodemographic characteristics and ecological momentary assessment completion in the 10‐week Hypo‐METRICS study: Hypoglycaemia MEasurements ThResholds and ImpaCtS
20243 citationsauthor #16
Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials
20244 citationsauthor #13
Exercise Barriers in Type 1 Diabetes: Fear of Hypoglycemia Predictors
20240 citationsauthor #5
The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode
20242 citationsauthor #6
Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study
20245 citationsauthor #12
Relationship Between Sensor-Detected Hypoglycemia and Patient-Reported Hypoglycemia in People With Type 1 and Insulin-Treated Type 2 Diabetes: The Hypo-METRICS Study
202424 citationsauthor #13
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa
202454 citationsauthor #6
The impact of hypoglycaemia on daily functioning among adults with diabetes: a prospective observational study using the Hypo-METRICS app
202416 citationsauthor #14
Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy
202418 citationsauthor #18
Association between recent exposure to continuous glucose monitoring‐recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes
20243 citationsauthor #8
Development of a new health-related quality of life measure for people with diabetes who experience hypoglycaemia: the Hypo-RESOLVE QoL
20242 citationsauthor #11
Ongoing burden and recent trends in severe hospitalised hypoglycaemia events in people with type 1 and type 2 diabetes in Scotland: A nationwide cohort study 2016-2022.
20246 citationsauthor #8
Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy
202411 citationsauthor #3
Correction: Cold-induced dishabituation in rodents exposed to recurrent hypoglycaemia
20240 citationsauthor #9
Trajectories of BMI before and after diagnosis of type 2 diabetes in a real-world population
20243 citationsauthor #2
Association between impaired awareness of hypoglycaemia and psychological outcomes in people living with insulin-treated type 2 diabetes
20240 citationsauthor #8
251-OR: The Impact of Identifying Sleep with a Fitbit on Calculated Rates of Nocturnal Hypoglycemia—The Hypo-Metrics Study
20230 citationsauthor #10
Metformin increases the uptake of glucose into the gut from the circulation in high-fat diet-fed male mice, which is enhanced by a reduction in whole-body Slc2a2 expression
20237 citationsauthor #8
Hypoglycaemia induces a sustained pro‐inflammatory response in people with type 1 diabetes and healthy controls
20239 citationsauthor #6
388-P: The Impact of Routine CGM on Hypoglycemia Rates and Psychological Outcomes in the Hypo-METRICS Study
20231 citationsauthor #8
Chronic hyperglycaemia increases the vulnerability of the hippocampus to oxidative damage induced during post-hypoglycaemic hyperglycaemia in a mouse model of chemically induced type 1 diabetes
202311 citationsauthor #10
The C5aR1 complement receptor: A novel immunomodulator of insulin action in skeletal muscle.
20235 citationsauthor #3
Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia
20237 citationsauthor #7
392-P: Optimizing Duration and Threshold of Sensor Glucose for Identifying Symptomatic Hypoglycemia in Insulin-Treated Diabetes—Hypo-METRICS Study
20230 citationsauthor #11
ONWARDS and upwards for basal insulin.
20230 citationsauthor #1
Assessing the Content Validity, Acceptability, and Feasibility of the Hypo-METRICS App: Survey and Interview Study
20237 citationsauthor #10
243-LB: C5a Receptor (C5aR1) Antagonism Ameliorates Saturated Fatty Acid–Induced Mitochondrial Dysfunction in Skeletal Muscle Cells
20230 citationsauthor #3
Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
202324 citationsauthor #17
250-OR: Majority of Sensor Hypoglycemia Is Not Detected by People Living with Diabetes—Hypo-METRICS Study
20231 citationsauthor #8
Abstract reviewers
20230 citationsauthor #32
775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis
20230 citationsauthor #3
391-P: Individualized Optimization of Duration and Threshold of Sensor Hypoglycemia Improves Identification of Symptomatic Hypoglycemia Episodes—Hypo-METRICS Study
20230 citationsauthor #12
Psychometric properties of an innovative smartphone application to investigate the daily impact of hypoglycemia in people with type 1 or type 2 diabetes: The Hypo-METRICS app
20238 citationsauthor #15
High intensity interval training as a novel treatment for impaired awareness of hypoglycaemia in people with type 1 diabetes (HIT4HYPOS): a randomised parallel-group study
20238 citationsauthor #9
Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
202217 citationsauthor #9
689-P: Comparing the Rates of Sensor-Detected Hypoglycaemia and Patient-Reported Hypoglycaemia by Awareness of Hypoglycaemia Using Continuous Glucose Monitoring: The Hypo-METRICS Trial
20220 citationsauthor #7
iGlarLixi versus Basal Plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy
20221 citationsauthor #7
iGlarLixi versus Basal Plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy
20221 citationsauthor #1
833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial
20220 citationsauthor #8
845-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline HbA1c, Insulin Dose, and BMI
20220 citationsauthor #2
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes
2022115 citationsauthor #9
Correction to: The suitability of patient-reported outcome measures used to assess the impact of hypoglycaemia on quality of life in people with diabetes: a systematic review using COSMIN methods
20222 citationsauthor #7
iGlarLixi versus Basal Plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy
20220 citationsauthor #7
373-P: A Systematic Review and Meta-analysis of the Impact of Acute Hypoglycemia on Cognitive Function in Adults with Type 1 Diabetes
20221 citationsauthor #11
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
20223 citationsauthor #3
Producing a preference‐based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes: A mixed‐methods research protocol
20225 citationsauthor #12
Large socioeconomic gap in period life expectancy and life years spent with complications of diabetes in the Scottish population with type 1 diabetes, 2013–2018
20228 citationsauthor #12
Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review
202220 citationsauthor #6
260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study
20221 citationsauthor #1
Producing a preference-based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes
20221 citationsauthor #14
846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function
20220 citationsauthor #8
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
20225 citationsauthor #1
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
202213 citationsauthor #1
Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application
202217 citationsauthor #11
688-P: Comparing Rates of Sensor-Detected Hypoglycaemia and Patient-Reported Hypoglycaemia by Method of Glucose Monitoring: The Hypo-METRICS Trial
20220 citationsauthor #8
711-P: User Acceptability of Ecological Momentary Assessment to Report Hypoglycemia over Ten Weeks Using a Novel Smartphone Application in the Hypo-METRICS Study: Hypoglycemia Measurements, Thresholds and Impacts
20220 citationsauthor #10
The impact of hypoglycaemia on quality of life among adults with type 1 diabetes: Results from "YourSAY: Hypoglycaemia".
202216 citationsauthor #8
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
20221 citationsauthor #1
Sustained Pro-Inflammatory Effects of Hypoglycemia in People with Type 2 Diabetes and in People Without Diabetes.
202224 citationsauthor #6
Central deficiency of IL-6Ra in mice impairs glucose-stimulated insulin secretion
20224 citationsauthor #6
The 12-Item Hypoglycemia Impact Profile (HIP12): psychometric validation of a brief measure of the impact of hypoglycemia on quality of life among adults with type 1 or type 2 diabetes
20224 citationsauthor #8
Remembrance of things past: The consequences of recurrent hypoglycaemia in diabetes
20227 citationsauthor #1
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
202254 citationsauthor #14
Consistent Effects of Hypoglycemia on Cognitive Function in People With or Without Diabetes
202240 citationsauthor #10
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
20225 citationsauthor #2
Using Data to Improve the Management of Diabetes: The Tayside Experience.
20227 citationsauthor #4
Hypo‐METRICS: Hypoglycaemia—MEasurement, ThResholds and ImpaCtS—A multi‐country clinical study to define the optimal threshold and duration of sensor‐detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol
202219 citationsauthor #14
iGlarLixi versus Basal Plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy
20220 citationsauthor #1
Visualising the heterogeneity in phenotype, disease progression and drug response in a large population with type 2 diabetes
20220 citationsauthor #10
Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis
202138 citationsauthor #7
Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study.
202178 citationsauthor #7
The suitability of patient-reported outcome measures used to assess the impact of hypoglycaemia on quality of life in people with diabetes: a systematic review using COSMIN methods
202118 citationsauthor #7
Clinical approaches to treat impaired awareness of hypoglycaemia
202130 citationsauthor #2
749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe
20210 citationsauthor #12
1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial
20211 citationsauthor #1
Adipocyte integrin-linked kinase plays a key role in the development of diet-induced adipose insulin resistance in male mice
202121 citationsauthor #6
746-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal Hypoglycemia in the SoliMix Trial
20210 citationsauthor #1

TIMELINE

1991 18 citations

1994 106 citations

1995 563 citations

1996 88 citations

1997 87 citations

1998 208 citations

1999 96 citations

2002 85 citations

2003 300 citations

2004 315 citations

2005 358 citations

2006 456 citations

2007 666 citations

2008 371 citations

2009 339 citations

2010 778 citations

2011 18 citations

2012 1,076 citations

2013 106 citations

2014 220 citations

2015 637 citations

2016 515 citations

2017 1,146 citations

2018 380 citations

2019 3,308 citations

2020 1,032 citations

2021 447 citations

2022 390 citations

2023 88 citations

2024 175 citations

2025 32 citations

2026 0 citations

Unknown 1 citations

R. McCrimmon

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT